Navigation Links
Sihuan's First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
Date:5/25/2012

HONG KONG, May 25, 2012 /PRNewswire-Asia/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise ("CCV") in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection ("Roxatidine"), Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration ("SFDA"). Expecting to obtain approval for production in the next three months, the Company plans to launch the drug to the market in the second half of the year, with hospitals as its major target market. It will be manufactured by Beijing Sihuan Pharmaceutical Co., Ltd., a wholly-owned manufacturing subsidiary.

Roxatidine is the fourth generation H2 receptor antagonist. The drug is categorized into two formulations - oral and injectable. The oral form of the drug was first launched in Japan in 1986 and is mainly used for gastric and duodenal ulcers, zollinger-ellison syndrome, reflux esophagitis and gastritis. The injectable form of the drug, which debuted in Japan in, is mainly used for upper gastrointestinal bleeding and pre-anesthesia application. Currently, Roxatidine is widely used in various countries, including Korea, Germany, Italy, the Netherlands, Greece and South Africa.  

Compared with other H2 receptor antagonists, the Roxatidine contains higher selectivity for H2 receptors and features a stronger effect on acid suppression. In addition, it contains a protective mucosal effect that other H2 receptors do not have. Although the Roxatidine has similar therapeutic efficacy to Proton pump inhibitors, it is safer, more stable and more cost-effective. These outstanding advantages are a testament to Roxatidine's clinical value. As a result, Roxatidine has been the first-line drug used for upper gastrointestinal bleeding in the overseas markets.

Gastrointestinal ulcers and bleeding is a common disease in China and has a significant patient base. With the fast-paced living environment, accelerated urbanization and the persistently high stress levels, the incidence rate of such diseases has been increasing each year. Overall incidences of digestive diseases afflict 10% - 20% of the total population and have high recurrence rates. As at the end of 2011, the size of the market has reached RMB$25 billion, bringing promising market potential and prospects.

Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said, "Capitalising on the characteristics and advantages of Roxatidine, along with Sihuan Pharmaceutical's strong sales and marketing capabilities and nationwide sales network, we believe that this drug will bring its clinical therapeutic value into play with wide clinical use. Building on its leading position in the CCV drug market, Sihuan Pharmaceutical's launch of Roxatidine signifies Sihuan Pharmaceutical's foray into the digestive system therapeutic area. This strategic move is set to further promote the continued development and growth of Sihuan, thereby creating lucrative returns for the Company and its shareholders."

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China's prescription market. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network and strong research and development capabilities. Its major products such as Kelinao, Anjieli, Chuanqing, Qu'Ao GM1 and Oudimei are widely used in the treatment of various cardio-cerebral vascular diseases.

For further enquiries, please contact Hill+Knowlton Strategies Asia.

Angela Kung
Tel: (852) 2894 6374 / 6017 7030
Email: angela.kung@hkstrategies.com

Ada Ho
Tel: (852) 2894 6290 / 9240 8639
Email: ada.ho@hkstrategies.com


'/>"/>
SOURCE Sihuan Pharmaceutical Holdings Group Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
3. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
4. Mylan Launches Generic Version of Viramune® Tablets
5. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
6. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
7. Mylan Launches Generic Version of Plavix® Tablets
8. Mylan Launches Generic Lipitor® in Five European Countries
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. Mylan Launches Generic Version of Zyprexa® Tablets
11. Watson Launches Generic FORTAMET(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):